Biomarkers for Inflammatory Bowel Disease

Patent metadata

Field	Value
Publication number	US-10640829-B2
Application number	US-201816159114-A
Country	US
Kind code	B2
Filing date	Oct 12, 2018
Priority date	Jul 5, 2016
Publication date	May 5, 2020
Grant date	May 5, 2020

Abstract

The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.

First claim

The invention claimed is:

1. An array of cDNAs of a whole blood sample of a subject suffering from inflammatory bowel disease (IBD), said array comprising:
a plurality of individual cDNA aliquots, wherein a first cDNA aliquot comprises a first RT-qPCR primer pair specific for a first selected gene, wherein at least a second and a third cDNA aliquot individually comprises an RT-qPCT primer pair specific for second and third genes, respectively, wherein said first, second and third selected genes are different genes;
wherein said first primer pair is specific for a LINC01136 gene and said second and third primer pairs, individually, are specific for two genes selected from the group consisting of: ARRDC4, GBP5, P2RY14, VTRNA1-1, IL18RAP, HP, NUDT7, GZMH, TRGC2, GZMK, LGALSL, FCRL5, IFI44L, LY96, and TRGV3;
wherein said array consists of no more than 16 primer pairs specific for said 16 genes, with the proviso that said array can comprise one or more control primer pairs
wherein said first, second and third primer pairs and no more than 16 primer pairs serve to detect expression of said first, second and third and no more than 16 genes to indicate a high risk or a low risk phenotype of IBD, and wherein said one or more control primer pairs do not serve to indicate a high risk or a low risk phenotype of IBD.

2. The array of claim 1 , wherein said array comprises said first, second and third cDNA aliquot comprising said first, second and third primer pairs and a fourth cDNA aliquot comprising a fourth primer pair specific for a fourth gene selected from said group.

3. The array of claim 1 , consisting of ten cDNA aliquots comprising ten primer pairs specific for ten genes selected from said group.

4. The array of claim 2 , consisting of sixteen cDNA aliquots comprising sixteen primer pairs specific for sixteen genes selected from said group.

5. The array of claim 1 , said array consisting of said plurality of individual cDNA aliquots, wherein each of said first, second and third cDNA aliquots comprises an RT-qPCR probe which is specific for said first, second and third selected gene, respectively.

6. The array of claim 1 , wherein said second cDNA aliquot comprises a fourth RT-qPCR primer pair specific for a fourth gene of said group, wherein said third cDNA aliquot comprises a fifth RT-qPCR primer pair specific for a fifth gene of said group, wherein said first, second, third, fourth and fifth genes of said group are different genes.

Assignees

• Cambridge Entpr Ltd

Inventors

• Lyons Paul A
• Smith Kenneth G C
• Mckinney Eoin F
• Biasci Daniele
• Lee James

Classifications

• C12Q2600/136

  Screening for pharmacological compounds · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title